Unveiling DENND2D as a Novel Prognostic Biomarker for Prostate Cancer Recurrence: From Gene to Prognosis
Open Access
- 26 December 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 25
Abstract
Background: Prostate cancer is a major global health burden, with biochemical recurrence (BCR) following radical prostatectomy affecting 20–40% of patients and posing significant challenges to prognosis and treatment. Emerging evidence suggests a critical role for differentially expressed in normal and neoplastic cell (DENN) domain-containing genes in oncogenesis; however, their implications in prostate cancer and BCR risk remain underexplored. Methods: This study systematically evaluated 151 single-nucleotide polymorphisms in DENN domain-containing genes in 458 patients with prostate cancer and BCR, followed by validation in an independent cohort of 185 patients. Results: Multivariate Cox regression analyses identified DENND2D rs610261 G>A as significantly associated with improved BCR-free survival in both cohorts (adjusted hazard ratio = 0.39, 95% confidence interval = 0.23–0.66, p = 0.001). Functional analysis revealed rs610261’s regulatory potential, with the protective A allele correlating with increased DENND2D expression in various human tissues. Compared to normal prostate tissues, DENND2D expression was reduced in prostate cancer, with higher expression being linked to favorable patient prognosis (p = 0.03). Gene set enrichment analysis revealed an association between DENND2D expression and the negative regulation of MYC target genes, including MAD2L1, ERH, and CLNS1A, which are overexpressed in prostate cancer and associated with poor survival. Furthermore, the elevated DENND2D expression promotes immune infiltration in prostate cancer, supporting its role in immune modulation. Conclusions: DENND2D is a prognostic biomarker for BCR in prostate cancer and offers new avenues for personalized treatment strategies.Keywords
Funding Information
- National Science and Technology Council of Taiwan (110-2314-B-002-113, 111-2314-B-002-240-MY3, 111-2320-B-039-021-MY3, 111-2218-E-037-001, 112-2314-B-037-127, KMUH109-9R63, KMUH109-9R64, KMUH112-2R59, NHRIKMU-111-I002, CMU111-MF-09, CMU112-MF-10, CMU113-MF-11)
- Kaohsiung Medical University (110-2314-B-002-113, 111-2314-B-002-240-MY3, 111-2320-B-039-021-MY3, 111-2218-E-037-001, 112-2314-B-037-127, KMUH109-9R63, KMUH109-9R64, KMUH112-2R59, NHRIKMU-111-I002, CMU111-MF-09, CMU112-MF-10, CMU113-MF-11)
- China Medical University (110-2314-B-002-113, 111-2314-B-002-240-MY3, 111-2320-B-039-021-MY3, 111-2218-E-037-001, 112-2314-B-037-127, KMUH109-9R63, KMUH109-9R64, KMUH112-2R59, NHRIKMU-111-I002, CMU111-MF-09, CMU112-MF-10, CMU113-MF-11)
This publication has 40 references indexed in Scilit:
- Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate CancerJAMA Oncology, 2021
- Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence PostprostatectomyEuropean Urology, 2018
- Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant GliomaCancer Cell, 2017
- A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate CancerEuropean Urology, 2015
- Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancerInternational Journal of Cancer, 2014
- Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancerGastric Cancer, 2014
- Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2DLung Cancer, 2013
- An Assembly Chaperone Collaborates with the SMN Complex to Generate Spliceosomal SnRNPsCell, 2008
- Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomyUrology, 2003
- Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate CancerJournal of Urology, 2003